# First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025.

*business · news · 2026-04-29 · The Manila Times*

## Key points

- FDA approved Otarmeni as the first gene therapy for genetic hearing loss, provided free in the U.S.
- Regeneron reached a U.S. government agreement for Most-Favored-Nation pricing and tariff relief for three years.
- Dupixent received new FDA and EC approvals for chronic spontaneous urticaria in young children.
- FDA extended EYLEA HD dosing intervals up to five months for wAMD and DME.
- Regeneron and Samsung settled patent litigation, blocking EYLEA biosimilar U.S. launch until January 2027.

**Companies:** Regeneron Pharmaceuticals, Inc., Sanofi
**Countries:** United States, Japan, Ireland

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/29/tmt-newswire/globenewswire/regeneron-reports-first-quarter-2026-financial-and-operating-results/2331307)

---

Canonical: https://newsio.io/n/88e93904-99b0-45dc-805d-84b67ec27e7c/first-quarter-2026-revenues-increased-19-to-3-6-billion-versus-first-quarter-202
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works